Last reviewed · How we verify

Unknown indication — Treatment Landscape & Competitive Intelligence

Unknown indication (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Unknown indication, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
omeprazole, 20mg twice daily omeprazole, 20mg twice daily Tel-Aviv Sourasky Medical Center Proton Pump Inhibitor (PPI) H+/K+ ATPase enzyme
Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI Orion Corporation, Orion Pharma Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA) Glucocorticoid receptors and β2-adrenergic receptors
Ceftriaxone v penicillin and gentamicin Ceftriaxone v penicillin and gentamicin Kamuzu University of Health Sciences Third-generation cephalosporin Penicillin-binding proteins (PBPs)
Captopril Test Dose and Trandolapril Captopril Test Dose and Trandolapril Rigshospitalet, Denmark Angiotensin-converting enzyme (ACE) inhibitors Angiotensin-converting enzyme (ACE)
BiDil XR BiDil XR Arbor Pharmaceuticals, Inc. Vasodilators Vasculature and cardiac function
Drug treatment with Cymbalta Drug treatment with Cymbalta Jefferson Clinic, P.C. Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin and norepinephrine transporters
Attenuated Hepatitis A Vaccine, H2 Strain Attenuated Hepatitis A Vaccine, H2 Strain Jiangsu Province Centers for Disease Control and Prevention Live attenuated vaccine Hepatitis A virus
Fluvastatin, Tacrolimus, Mycophenolat Mofetil Fluvastatin, Tacrolimus, Mycophenolat Mofetil University Hospital Schleswig-Holstein ["Statins", "Immunosuppressants", "Immunosuppressants"] ["HMG-CoA reductase", "T-cell activation", "IMP dehydrogenase"]
Montelukast (High FeNO group) Montelukast (High FeNO group) Hull University Teaching Hospitals NHS Trust Leukotriene receptor antagonist CysLT1 receptor
Actos (Pioglitazone) Actos (Pioglitazone) Taipei Veterans General Hospital, Taiwan Thiazolidinediones PPAR-γ

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 21 drugs in Unknown indication
  2. · 10 drugs in Unknown indication
  3. Taipei Veterans General Hospital, Taiwan · 3 drugs in Unknown indication
  4. Oslo University Hospital · 2 drugs in Unknown indication
  5. Pfizer Inc. · 2 drugs in Unknown indication
  6. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 2 drugs in Unknown indication
  7. Novartis Pharmaceuticals · 2 drugs in Unknown indication
  8. Assistance Publique - Hôpitaux de Paris · 1 drug in Unknown indication
  9. Arbor Pharmaceuticals, Inc. · 1 drug in Unknown indication
  10. ANRS, Emerging Infectious Diseases · 1 drug in Unknown indication
  11. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 drug in Unknown indication
  12. Azienda Policlinico Umberto I · 1 drug in Unknown indication

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Unknown indication:

Cite this brief

Drug Landscape (2026). Unknown indication — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/unknown-indication. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing